|
nasdaq:drrx
|
34150
|
Apr 14th, 2024 12:00AM
|
DURECT Corporation
|
2.0K
|
110.00
|
Open
|
|
Apr 13th, 2024 10:56PM
|
Apr 14th, 2024 10:54AM
|
DURECT is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer. Larsucosterol, DURECT’s lead drug candidate, binds to and inhibits the activity of DNA methyltransferases (DNMTs), epigenetic enzymes that are elevated and associated with hypermethylation found in alcohol-associated hepatitis (AH) patients. Larsucosterol is in clinical development for the potential treatment of AH, for which FDA has granted a Fast Track Designation; non-alcoholic steatohepatitis (NASH) is also being explored. In addition, POSIMIR® (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the innovative SABER® platform technology, is FDA-approved and is exclusively licensed to Innocoll Pharmaceuticals for sale and distribution in the United States.
|
Open
|
|
Open
|
|
|
|
|
|
|
Durect
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:drrx
|
34150
|
Apr 13th, 2024 12:00AM
|
DURECT Corporation
|
2.0K
|
110.00
|
Open
|
|
Apr 12th, 2024 10:47PM
|
Apr 13th, 2024 11:22AM
|
DURECT is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer. Larsucosterol, DURECT’s lead drug candidate, binds to and inhibits the activity of DNA methyltransferases (DNMTs), epigenetic enzymes that are elevated and associated with hypermethylation found in alcohol-associated hepatitis (AH) patients. Larsucosterol is in clinical development for the potential treatment of AH, for which FDA has granted a Fast Track Designation; non-alcoholic steatohepatitis (NASH) is also being explored. In addition, POSIMIR® (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the innovative SABER® platform technology, is FDA-approved and is exclusively licensed to Innocoll Pharmaceuticals for sale and distribution in the United States.
|
Open
|
|
Open
|
|
|
|
|
|
|
Durect
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:drrx
|
34150
|
Apr 12th, 2024 12:00AM
|
DURECT Corporation
|
2.0K
|
110.00
|
Open
|
|
Apr 11th, 2024 10:52PM
|
Apr 12th, 2024 08:17AM
|
DURECT is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer. Larsucosterol, DURECT’s lead drug candidate, binds to and inhibits the activity of DNA methyltransferases (DNMTs), epigenetic enzymes that are elevated and associated with hypermethylation found in alcohol-associated hepatitis (AH) patients. Larsucosterol is in clinical development for the potential treatment of AH, for which FDA has granted a Fast Track Designation; non-alcoholic steatohepatitis (NASH) is also being explored. In addition, POSIMIR® (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the innovative SABER® platform technology, is FDA-approved and is exclusively licensed to Innocoll Pharmaceuticals for sale and distribution in the United States.
|
Open
|
|
Open
|
|
|
|
|
|
|
Durect
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:drrx
|
34150
|
Apr 11th, 2024 12:00AM
|
DURECT Corporation
|
2.0K
|
110.00
|
Open
|
|
Apr 10th, 2024 11:25PM
|
Apr 11th, 2024 11:02AM
|
DURECT is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer. Larsucosterol, DURECT’s lead drug candidate, binds to and inhibits the activity of DNA methyltransferases (DNMTs), epigenetic enzymes that are elevated and associated with hypermethylation found in alcohol-associated hepatitis (AH) patients. Larsucosterol is in clinical development for the potential treatment of AH, for which FDA has granted a Fast Track Designation; non-alcoholic steatohepatitis (NASH) is also being explored. In addition, POSIMIR® (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the innovative SABER® platform technology, is FDA-approved and is exclusively licensed to Innocoll Pharmaceuticals for sale and distribution in the United States.
|
Open
|
|
Open
|
|
|
|
|
|
|
Durect
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:drrx
|
34150
|
Apr 10th, 2024 12:00AM
|
DURECT Corporation
|
2.0K
|
110.00
|
Open
|
|
Apr 9th, 2024 10:55PM
|
Apr 10th, 2024 05:10PM
|
DURECT is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer. Larsucosterol, DURECT’s lead drug candidate, binds to and inhibits the activity of DNA methyltransferases (DNMTs), epigenetic enzymes that are elevated and associated with hypermethylation found in alcohol-associated hepatitis (AH) patients. Larsucosterol is in clinical development for the potential treatment of AH, for which FDA has granted a Fast Track Designation; non-alcoholic steatohepatitis (NASH) is also being explored. In addition, POSIMIR® (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the innovative SABER® platform technology, is FDA-approved and is exclusively licensed to Innocoll Pharmaceuticals for sale and distribution in the United States.
|
Open
|
|
Open
|
|
|
|
|
|
|
Durect
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:drrx
|
34150
|
Apr 9th, 2024 12:00AM
|
DURECT Corporation
|
2.0K
|
110.00
|
Open
|
|
Apr 8th, 2024 11:06PM
|
Apr 9th, 2024 09:51AM
|
DURECT is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer. Larsucosterol, DURECT’s lead drug candidate, binds to and inhibits the activity of DNA methyltransferases (DNMTs), epigenetic enzymes that are elevated and associated with hypermethylation found in alcohol-associated hepatitis (AH) patients. Larsucosterol is in clinical development for the potential treatment of AH, for which FDA has granted a Fast Track Designation; non-alcoholic steatohepatitis (NASH) is also being explored. In addition, POSIMIR® (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the innovative SABER® platform technology, is FDA-approved and is exclusively licensed to Innocoll Pharmaceuticals for sale and distribution in the United States.
|
Open
|
|
Open
|
|
|
|
|
|
|
Durect
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:drrx
|
34150
|
Apr 8th, 2024 12:00AM
|
DURECT Corporation
|
2.0K
|
110.00
|
Open
|
|
Apr 7th, 2024 11:31PM
|
Apr 8th, 2024 06:49PM
|
DURECT is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer. Larsucosterol, DURECT’s lead drug candidate, binds to and inhibits the activity of DNA methyltransferases (DNMTs), epigenetic enzymes that are elevated and associated with hypermethylation found in alcohol-associated hepatitis (AH) patients. Larsucosterol is in clinical development for the potential treatment of AH, for which FDA has granted a Fast Track Designation; non-alcoholic steatohepatitis (NASH) is also being explored. In addition, POSIMIR® (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the innovative SABER® platform technology, is FDA-approved and is exclusively licensed to Innocoll Pharmaceuticals for sale and distribution in the United States.
|
Open
|
|
Open
|
|
|
|
|
|
|
Durect
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:drrx
|
34150
|
Apr 7th, 2024 12:00AM
|
DURECT Corporation
|
2.0K
|
110.00
|
Open
|
|
Apr 6th, 2024 11:02PM
|
Apr 6th, 2024 11:02PM
|
DURECT is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer. Larsucosterol, DURECT’s lead drug candidate, binds to and inhibits the activity of DNA methyltransferases (DNMTs), epigenetic enzymes that are elevated and associated with hypermethylation found in alcohol-associated hepatitis (AH) patients. Larsucosterol is in clinical development for the potential treatment of AH, for which FDA has granted a Fast Track Designation; non-alcoholic steatohepatitis (NASH) is also being explored. In addition, POSIMIR® (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the innovative SABER® platform technology, is FDA-approved and is exclusively licensed to Innocoll Pharmaceuticals for sale and distribution in the United States.
|
Open
|
|
Open
|
|
|
|
|
|
|
Durect
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:drrx
|
34150
|
Apr 6th, 2024 12:00AM
|
DURECT Corporation
|
2.0K
|
110.00
|
Open
|
|
Apr 5th, 2024 11:02PM
|
Apr 5th, 2024 11:02PM
|
DURECT is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer. Larsucosterol, DURECT’s lead drug candidate, binds to and inhibits the activity of DNA methyltransferases (DNMTs), epigenetic enzymes that are elevated and associated with hypermethylation found in alcohol-associated hepatitis (AH) patients. Larsucosterol is in clinical development for the potential treatment of AH, for which FDA has granted a Fast Track Designation; non-alcoholic steatohepatitis (NASH) is also being explored. In addition, POSIMIR® (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the innovative SABER® platform technology, is FDA-approved and is exclusively licensed to Innocoll Pharmaceuticals for sale and distribution in the United States.
|
Open
|
|
Open
|
|
|
|
|
|
|
Durect
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:drrx
|
34150
|
Apr 5th, 2024 12:00AM
|
DURECT Corporation
|
2.0K
|
110.00
|
Open
|
|
Apr 4th, 2024 11:29PM
|
Apr 4th, 2024 11:29PM
|
DURECT is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer. Larsucosterol, DURECT’s lead drug candidate, binds to and inhibits the activity of DNA methyltransferases (DNMTs), epigenetic enzymes that are elevated and associated with hypermethylation found in alcohol-associated hepatitis (AH) patients. Larsucosterol is in clinical development for the potential treatment of AH, for which FDA has granted a Fast Track Designation; non-alcoholic steatohepatitis (NASH) is also being explored. In addition, POSIMIR® (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the innovative SABER® platform technology, is FDA-approved and is exclusively licensed to Innocoll Pharmaceuticals for sale and distribution in the United States.
|
Open
|
|
Open
|
|
|
|
|
|
|
Durect
|
Health Care
|
Pharmaceuticals & Biotechnology
|